2026 H1 -tulosraportti
UUTTA
6 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 4 528 | - | - | ||
| 7 000 | - | - | ||
| 500 | - | - | ||
| 409 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 min sittenSince there's so much talk about dnb, I'll throw this one in again. Seems like it was forgotten. THOR MEDICAL: ARCTIC RAISES TARGET PRICE TO 8.7 (5), REITERATES BUY Close 1 Sep. 08:10 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the target price on Thor Medical to 8.7 kroner per share, from a previous 5 kroner, and reiterates a buy recommendation on the share after an analyst change, according to an analysis Monday evening. The brokerage believes today's share price significantly undervalues the company's long-term potential. "In particular, we believe that the market undervalues the demand for isotopes that arises as a result of waste throughout the radiopharmaceutical value chain. We also believe that the self-scaling economy in Thor Medical's production process, where reusable Th-232 raw material builds up over time, is not fully reflected in the share price. Our new bottom-up analysis explicitly models both these effects and thus provides a more detailed picture of the company's long-term revenue and margin potential", writes the brokerage.
·2 t sittenI think the talk about an imminent share issue is getting a bit out of hand. Yes, Thor Medical had 59.9 million NOK in cash at the half-year, and the financing must of course be monitored. But you can't just look at the cash balance and conclude that "now there will be a share issue". The money has, among other things, been used to build and complete AlphaOne and to build up raw material inventory for production. The factory was completed on time and within budget, commercial production has started, and the first customer delivery has already been completed. At the same time, the company has 40 million NOK in unutilized credit facilities. The most important thing for me is that Thor has now gone from building a factory to actually producing and delivering. They also have about 850 million NOK in long-term Th-228 delivery agreements. Of course, that's not the same as 850 million in cash tomorrow, but it shows that there is already significant demand going forward. And then try to see how disagreed the analysts are: Arctic Securities has just raised the price target from 5.00 to 8.70 NOK and says BUY. DNB Carnegie simultaneously raises its own price target from 3.50 to 4.20, but maintains SELL. Two professional analysis houses thus look at the same company and arrive at widely different values. That tells more about the uncertainty in the valuation than about one price necessarily being "the right one". For me, the case is therefore still strong: construction delivered on time and budget, raw materials in stock, production started, first delivery completed, large order/agreement book and now commercial ramp-up. The big test will be how quickly it is converted into growing sales and eventually positive operations. People must of course be positive or negative about the stock. Some own it, others might be waiting for a lower entry point. But rumors and wishes for cheaper shares are not the same as a company announcement. I have not yet seen documentation that Thor has decided on a new share issue. So I take the debate with a grain of salt and prefer to follow what the company actually delivers. So far, Thor has delivered on several of the most important milestones.
It is a good argument, but it changes nothing about the fact that earnings were far less than expected. Then it is clear that questions arise about the actual real need for the product. If the expected earnings are now anticipated further in the future, then capital migrates elsewhere. That is what we are seeing now. It is crucial that Thor's management is good at reporting and explaining.
·3 t sittenBought a small position for 700k, awaiting emission and cheap shares. One knows not to fall in love with a company, but oh well. Have been in Thor since 0.7kr per share. Sold out at 4 kroner, and have been out for a while. So glad to finally be home again. Good luck everyone
700k is a solid position, that😎 Do you have a portfolio of almost 100mill?? Impressive👌
·4 t sittenIs it uncertainty about whether TRMED needs new financing / an equity issue until operations become cash-positive that is driving the share price down?
There is no imminent danger it gives before the expansion of the factory. There is nothing to suggest that it will come now. Now they do have income too.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
UUTTA
6 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sittenSince there's so much talk about dnb, I'll throw this one in again. Seems like it was forgotten. THOR MEDICAL: ARCTIC RAISES TARGET PRICE TO 8.7 (5), REITERATES BUY Close 1 Sep. 08:10 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the target price on Thor Medical to 8.7 kroner per share, from a previous 5 kroner, and reiterates a buy recommendation on the share after an analyst change, according to an analysis Monday evening. The brokerage believes today's share price significantly undervalues the company's long-term potential. "In particular, we believe that the market undervalues the demand for isotopes that arises as a result of waste throughout the radiopharmaceutical value chain. We also believe that the self-scaling economy in Thor Medical's production process, where reusable Th-232 raw material builds up over time, is not fully reflected in the share price. Our new bottom-up analysis explicitly models both these effects and thus provides a more detailed picture of the company's long-term revenue and margin potential", writes the brokerage.
- ·2 t sittenI think the talk about an imminent share issue is getting a bit out of hand. Yes, Thor Medical had 59.9 million NOK in cash at the half-year, and the financing must of course be monitored. But you can't just look at the cash balance and conclude that "now there will be a share issue". The money has, among other things, been used to build and complete AlphaOne and to build up raw material inventory for production. The factory was completed on time and within budget, commercial production has started, and the first customer delivery has already been completed. At the same time, the company has 40 million NOK in unutilized credit facilities. The most important thing for me is that Thor has now gone from building a factory to actually producing and delivering. They also have about 850 million NOK in long-term Th-228 delivery agreements. Of course, that's not the same as 850 million in cash tomorrow, but it shows that there is already significant demand going forward. And then try to see how disagreed the analysts are: Arctic Securities has just raised the price target from 5.00 to 8.70 NOK and says BUY. DNB Carnegie simultaneously raises its own price target from 3.50 to 4.20, but maintains SELL. Two professional analysis houses thus look at the same company and arrive at widely different values. That tells more about the uncertainty in the valuation than about one price necessarily being "the right one". For me, the case is therefore still strong: construction delivered on time and budget, raw materials in stock, production started, first delivery completed, large order/agreement book and now commercial ramp-up. The big test will be how quickly it is converted into growing sales and eventually positive operations. People must of course be positive or negative about the stock. Some own it, others might be waiting for a lower entry point. But rumors and wishes for cheaper shares are not the same as a company announcement. I have not yet seen documentation that Thor has decided on a new share issue. So I take the debate with a grain of salt and prefer to follow what the company actually delivers. So far, Thor has delivered on several of the most important milestones.It is a good argument, but it changes nothing about the fact that earnings were far less than expected. Then it is clear that questions arise about the actual real need for the product. If the expected earnings are now anticipated further in the future, then capital migrates elsewhere. That is what we are seeing now. It is crucial that Thor's management is good at reporting and explaining.
- ·3 t sittenBought a small position for 700k, awaiting emission and cheap shares. One knows not to fall in love with a company, but oh well. Have been in Thor since 0.7kr per share. Sold out at 4 kroner, and have been out for a while. So glad to finally be home again. Good luck everyone700k is a solid position, that😎 Do you have a portfolio of almost 100mill?? Impressive👌
- ·4 t sittenIs it uncertainty about whether TRMED needs new financing / an equity issue until operations become cash-positive that is driving the share price down?There is no imminent danger it gives before the expansion of the factory. There is nothing to suggest that it will come now. Now they do have income too.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 4 528 | - | - | ||
| 7 000 | - | - | ||
| 500 | - | - | ||
| 409 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
UUTTA
6 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sittenSince there's so much talk about dnb, I'll throw this one in again. Seems like it was forgotten. THOR MEDICAL: ARCTIC RAISES TARGET PRICE TO 8.7 (5), REITERATES BUY Close 1 Sep. 08:10 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the target price on Thor Medical to 8.7 kroner per share, from a previous 5 kroner, and reiterates a buy recommendation on the share after an analyst change, according to an analysis Monday evening. The brokerage believes today's share price significantly undervalues the company's long-term potential. "In particular, we believe that the market undervalues the demand for isotopes that arises as a result of waste throughout the radiopharmaceutical value chain. We also believe that the self-scaling economy in Thor Medical's production process, where reusable Th-232 raw material builds up over time, is not fully reflected in the share price. Our new bottom-up analysis explicitly models both these effects and thus provides a more detailed picture of the company's long-term revenue and margin potential", writes the brokerage.
- ·2 t sittenI think the talk about an imminent share issue is getting a bit out of hand. Yes, Thor Medical had 59.9 million NOK in cash at the half-year, and the financing must of course be monitored. But you can't just look at the cash balance and conclude that "now there will be a share issue". The money has, among other things, been used to build and complete AlphaOne and to build up raw material inventory for production. The factory was completed on time and within budget, commercial production has started, and the first customer delivery has already been completed. At the same time, the company has 40 million NOK in unutilized credit facilities. The most important thing for me is that Thor has now gone from building a factory to actually producing and delivering. They also have about 850 million NOK in long-term Th-228 delivery agreements. Of course, that's not the same as 850 million in cash tomorrow, but it shows that there is already significant demand going forward. And then try to see how disagreed the analysts are: Arctic Securities has just raised the price target from 5.00 to 8.70 NOK and says BUY. DNB Carnegie simultaneously raises its own price target from 3.50 to 4.20, but maintains SELL. Two professional analysis houses thus look at the same company and arrive at widely different values. That tells more about the uncertainty in the valuation than about one price necessarily being "the right one". For me, the case is therefore still strong: construction delivered on time and budget, raw materials in stock, production started, first delivery completed, large order/agreement book and now commercial ramp-up. The big test will be how quickly it is converted into growing sales and eventually positive operations. People must of course be positive or negative about the stock. Some own it, others might be waiting for a lower entry point. But rumors and wishes for cheaper shares are not the same as a company announcement. I have not yet seen documentation that Thor has decided on a new share issue. So I take the debate with a grain of salt and prefer to follow what the company actually delivers. So far, Thor has delivered on several of the most important milestones.It is a good argument, but it changes nothing about the fact that earnings were far less than expected. Then it is clear that questions arise about the actual real need for the product. If the expected earnings are now anticipated further in the future, then capital migrates elsewhere. That is what we are seeing now. It is crucial that Thor's management is good at reporting and explaining.
- ·3 t sittenBought a small position for 700k, awaiting emission and cheap shares. One knows not to fall in love with a company, but oh well. Have been in Thor since 0.7kr per share. Sold out at 4 kroner, and have been out for a while. So glad to finally be home again. Good luck everyone700k is a solid position, that😎 Do you have a portfolio of almost 100mill?? Impressive👌
- ·4 t sittenIs it uncertainty about whether TRMED needs new financing / an equity issue until operations become cash-positive that is driving the share price down?There is no imminent danger it gives before the expansion of the factory. There is nothing to suggest that it will come now. Now they do have income too.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 4 528 | - | - | ||
| 7 000 | - | - | ||
| 500 | - | - | ||
| 409 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt